Androgen receptor antagonist 1

Modify Date: 2024-01-03 09:12:36

Androgen receptor antagonist 1 Structure
Androgen receptor antagonist 1 structure
Common Name Androgen receptor antagonist 1
CAS Number 1338812-36-4 Molecular Weight 416.90
Density N/A Boiling Point N/A
Molecular Formula C21H25ClN4O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Androgen receptor antagonist 1


Androgen receptor antagonist 1 is an orally available full androgen receptor (AR) antagonist with an IC50 of 59 nM[1]. Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively[2].

 Names

Name Androgen receptor antagonist 1

 Androgen receptor antagonist 1 Biological Activity

Description Androgen receptor antagonist 1 is an orally available full androgen receptor (AR) antagonist with an IC50 of 59 nM[1]. Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively[2].
Related Catalog
Target

IC50: 59 nM (androgen receptor)[1]

In Vitro Androgen receptor antagonist 1 (Compound 26; 1 nM-100 μM) shows significant cell growth inhibition effects for LNCaP and LNAR cells but not DU145 cells[1]. Cell Proliferation Assay[1] Cell Line: Prostate cancer (CaP) cells (LNCAP, LNAR, and DU145) Concentration: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM Incubation Time: 7 days Result: Antiproliferative effects of in LNCAP and LNAR cells.
In Vivo Androgen receptor antagonist 1 (Compound 26; 100 mg/kg once a day for 5 weeks) demonstrates excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model[1]. Animal Model: Male athymic nude mice with LNCaP xenograft model of CRPC[1] Dosage: 100 mg/kg Administration: Orally once a day for 5 weeks Result: Demonstrated outstanding efficacy in inhibiting tumor growth. At the given doses (100 mg/kg once a day) nearly completely suppressed tumor growth (by 90 %) and the PSA levels (78%) after 5 weeks, with no detectable body weight loss for the period of time when animals were treated.
References

[1]. Guo C, et al. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem. 2011 Nov 10;54(21):7693-704.

[2]. Han X, et al. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964.

 Chemical & Physical Properties

Molecular Formula C21H25ClN4O3
Molecular Weight 416.90
InChIKey HJJNHDLYWZTKGQ-UHFFFAOYSA-N
SMILES CC1(C)C(NC(=O)c2cnn(CCO)c2)C(C)(C)C1Oc1ccc(C#N)c(Cl)c1

 Safety Information

Hazard Codes Xi
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.